The Patent Cliff Playbook: Pharmaceutical IP Valuation, Generic Entry Timing, and Biosimilar Strategy
A technical deep dive for pharma IP teams, R&D leads, and institutional investors Master Key Takeaways A drug’s market monopoly […]
Latin America Specialty Generics: The Complete IP, Regulatory & Market Entry Playbook
For pharma IP teams, portfolio managers, R&D leads, and institutional investors who need more than headline growth figures. Executive Summary
Latin America Specialty Generics: The Complete IP, Regulatory & Market Entry Playbook Read Post »
Drug Patent Marketing Strategy: The Complete Playbook for Maximizing Exclusivity, IP Value, and Peak Sales
A patent does not generate revenue. A masterfully executed commercial strategy does. This guide breaks down exactly how pharmaceutical companies,
The Real Cost of Generic Drug Production: A Full-Stack Analysis
1. The Structural Economics of Generic Affordability 1.1 The Arithmetic Behind the 80-85% Discount Generic drugs fill roughly 90% of
The Real Cost of Generic Drug Production: A Full-Stack Analysis Read Post »
Patent Term Extension Calculator: Step-by-Step Expert Guide
The economic lifeblood of a pharmaceutical company is the period of market exclusivity granted by its patent portfolio. For most
Patent Term Extension Calculator: Step-by-Step Expert Guide Read Post »
Biosimilar Clinical Trial Design: The Playbook That Wins Regulatory Approval
The global biologics market crossed $400 billion in annual revenue in 2023 and is tracking toward $600 billion by 2026
Biosimilar Clinical Trial Design: The Playbook That Wins Regulatory Approval Read Post »
Generic Drug Development in Emerging Markets: The IP, Regulatory, and Commercial Playbook
Section 1: What ‘Pharmerging’ Actually Means in 2025 Defining the Tier Structure IQVIA’s ‘pharmerging’ classification groups approximately 21 countries by
GMP in Generic Drug Manufacturing: The Complete Strategic Guide for Pharma Operators and Investors
Generics account for over 90% of all U.S. prescriptions filled while consuming roughly 18% of total prescription drug spending. That
The Regulatory Pathway for Generic Drugs: A Strategic Guide to Market Entry and Competitive Advantage
A data-driven deep dive into Hatch-Waxman mechanics, ANDA strategy, Paragraph IV litigation economics, patent IP valuation, complex generics science, and
